#SK bioscience
-
Business SK bioscience and KDCA initiate development of Avian influenza vaccine
By Diplomacy Journal Lee Kap-soo SK bioscience has been selected for the Korea Disease Control and Prevention Agency (KDCA)’s Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program, the company said on May 6. This government-led initiative aims to develop vaccines against avian influenza – identified as a high-risk candidate for the next pandemic. SK bioscience was chosen for its proven technological capabilities as the only domestic company to have commercialized cell-culture-based vaccines for both influenza and COVID-19. Under the program, SK bioscience and KDCA wil
- Lee 기자
- 2025-05-07 16:24
-
Business SK bioscience wins patent invalidation case against Moderna
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced on April 23 that it has won a final victory in a patent invalidation lawsuit against Moderna, the global developer of mRNA COVID-19 vaccines. SK bioscience filed the nullity suit over the Moderna’s patent on ‘Modified nucleosides, nucleotides, and nucleic acids and uses thereof’ in 2023. This is the only registered patent related to mRNA manufacturing technology in Korea. After nearly two years of review, the Korean Intellectual
- Lee 기자
- 2025-04-24 14:49
-
Business SK bioscience expands influenza vaccine exports to Southern Hemisphere market
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced on March 12 that the company has begun shipping its self-developed influenza vaccine, SKYCellflu, from its vaccine manufacturing facility L HOUSE to Southern Hemisphere markets, including Southeast Asia and Latin America. A total of 750,000 doses will be supplied in the first half of the year. This shipment marks the company’s second export of influenza vaccines for Southern Hemisphere use, following its initial export to Thailan
- Lee 기자
- 2025-03-12 11:02
-
Business SK bioscience secures additional PAHO contract to supply varicella vaccines to Latin America
By Diplomacy Journal Lee Kap-soo SK bioscience announced on February 28 that it has successfully secured additional orders for its self-developed chickenpox vaccine in the largest international procurement market in Latin America. This order comes as a result of prior notification from the Pan American Health Organization (PAHO), a UN agency, to supply its chickenpox vaccine, 'SkyVaricella,' to the Latin American region through 2027. The order was secured during PAHO's preliminary bidding process, and depending on the volume of orders from PAHO, SK bioscience will supply the chickenpox vaccine
- Lee 기자
- 2025-02-28 14:19
-
Business SK bioscience initiates global clinical trials for GBP560
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, on Feb. 25 announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. SK Bioscience’s development of vaccine for Japanese encephalitis could not only help to protect against Japanese Encephalitis but also pave the way to the development of an mRNA technology that could be potentially adapted in a matter of weeks to develop a vaccine against a novel as-yet-identified in
- Lee 기자
- 2025-02-25 11:29
-
Business SK bioscience joins hands with WHO to cope with infectious disease crisis
By Diplomacy Journal Lee Kap-soo SK bioscience has successfully completed a project as the only private company participating in a joint study organized by the World Health Organization (WHO) aimed at establishing an international standard for the SARS virus, in response to the global infectious disease crisis, the company said on Feb. 12. In October of last year, the WHO announced the international standard for the SARS virus, with SK bioscience playing a key role in conducting immunogenicity analysis during this process. The project involved 12 health authorities and institutions leading glo
- Lee 기자
- 2025-02-12 16:43
-
Business SK bioscience receives approval for global clinical trials
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced on Dec. 12 that it has received approval from the Human Research Ethics Committee (HREC) in Australia for the clinical trial protocols of a Phase 1/2 trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. SK bioscience is establishing its mRNA vaccine platform through the development of vaccines against Japanese encephalitis virus as well as Lassa fever virus. The Japanese Encephalitis Virus (viral family: Fla
- Lee 기자
- 2024-12-12 13:45
-
Business SK bioscience gets approval of Quadrivalent Influenza Vaccine in Indonesia
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced on Oct. 23 that the world’s first quadrivalent cell-cultured influenza vaccine, SKYCellflu Quadrivalent prefilled syringe, has been approved by Indonesia’s Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan). This marks the first time a domestically developed influenza vaccine has been licensed in Indonesia. Indonesia, the world’s fourth most populous nation with over 280 million people, boasts Southeast Asia’s largest e
- Lee 기자
- 2024-10-23 13:27
-
Business SK bioscience, CEPI deepen partnership to prevent infectious disease
By Diplomacy Journal Lee Kap-soo SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced on Aug. 30 that the company and the Coalition for Epidemic Preparedness Innovations (CEPI) hosted the 'Celebrating Partnership for Pandemic Preparedness: CEPI-SK bioscience Reception’ in Yeoui-do, Seoul on August 29. The CEPI Board and senior officials visited Korea this week to discuss global collaboration to prevent the spread of infectious diseases. Over 110 global health experts and leaders gathered at the event, organized to
- Lee 기자
- 2024-08-30 15:13
-
1
The U.S.-ROK alliance blossoms through art and culture
-
2
Buddha's birthday celebrated with blessing ceremony at temples nationwide
-
3
Hanwha Systems to develop the ‘Korean-style Iron Dome’
-
4
Azerbaijan holds an event to attract investment in Alat Free Economic Zone
-
5
Gyeongju City Mayor Joo receives Italian Ambassador Emilia Gatto
-
6
SK bioscience and IVI host 2025 Park Mahn Hoon Award
-
2025-05-08 16:38
SML Biopharm of Korea signs MOU with Affilogic of France
-
2025-05-08 16:09
Thai Amb. Sangrat lends support to Cheongju Airport runway construction
-
2025-05-08 12:04
2025 My K-Festa for global Hallyu fans to be held at Olympic Park
-
2025-05-08 10:51
'British Cultural Village' to be built in Gangseo-gu, Busan
-
2025-05-07 16:24
SK bioscience and KDCA initiate development of Avian influenza vaccine
Address: Doosan We've Pavilion 1203, Sambong-ro 81, Jongno-gu, Seoul
Date of first registration: Founded in 1996 as UN News, changed its name to The Diplomatic Journal in 2009
Registration No.: Jongno Ra00125/ Registration Date: 2009-04-14/ Registration Number: Seoul 아54606 / Registration Date: Dec. 13, 2022
Publisher: Damwha Media Group Chairman Lee Jon-young
Editor in Chief: Lee Jon-young/ Vice Chairman: Chung Bo-won/ Standing Advisor Lee Keon-chan / Senior Editorial Writer Ko Jae-hwe / Editorial Writer Lee Se-hoon / Managing Editor Lee Kap-soo/ Cultural Editor Lee Joon-seok/ Political Editor Lim Han-choong/ U.S. Branch Head Kim Joon-bae/ Business Editor Kayla Lee
Phone number: 02-3417-1010 | 02-396-5757
E-Mail: djournal3417@gmail.com
UPDATE: 2025년 05월 08일 16시 38분